 |
|
Statin Use and Risks for Death and Hospitalization in Chronic Heart Failure
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In their study examining the relationship between statin therapy and the risks for death and hospitalization in chronic heart failure, Dr Go and colleagues1 concluded that statin therapy was independently associated with lower risks of both death and hospitalization among patients with chronic heart failure, with or without coronary heart disease. Based upon the data presented, we have 2 concerns regarding their conclusions.
First, in reviewing the baseline medical characteristics (Table 2 in the article1), participants receiving a statin postdiagnosis may have had a higher likelihood of being treated with aspirin or other antiplatelet therapy. This is because current treatment algorithms for patients with angina, coronary artery bypass grafting, prior myocardial infarction, or percutaneous coronary interventions (all more common in the statin group) often include daily aspirin or other antiplatelet therapy. A significant proportional reduction in mortality due to vascular and nonvascular causes has been noted . . . [Full Text of this Article]
Wayne Gerard, MD
wayne.gerard@gfclinic.com
Great Falls Clinic
Great Falls, Mont
Julia Gerard, BS
Creighton University School of Pharmacy
Omaha, Neb
RELATED LETTERS
Statin Use and Risks for Death and Hospitalization in Chronic Heart Failure
Samy Suissa
JAMA. 2007;297(10):1057.
EXTRACT
| FULL TEXT
Statin Use and Risks for Death and Hospitalization in Chronic Heart Failure—Reply
Alan S. Go, Jingrong Yang, and Jerry H. Gurwitz
JAMA. 2007;297(10):1058.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Statin Therapy and Risks for Death and Hospitalization in Chronic Heart Failure
Alan S. Go, Wendy Y. Lee, Jingrong Yang, Joan C. Lo, and Jerry H. Gurwitz
JAMA. 2006;296(17):2105-2111.
ABSTRACT
| FULL TEXT
|
